Dexcom to Launch 15-Day Glucose Monitor in Canada

The new G7 continuous glucose monitoring system arrives for eligible Canadian patients this November 2026.

Updated on Oct. 28, 2026 in Diabetes

Dexcom to Launch 15-Day Glucose Monitor in Canada

Live Poll

Do you believe new medical tech features effectively reduce your daily stress in managing chronic health conditions?

Starting in November 2026, the Dexcom G7 15 Day continuous glucose monitoring system will be available for adults 18 and older living with diabetes in Canada. The launch coincides with the introduction of public and private health insurance coverage for the device.

Why it matters

The system is engineered to decrease the frequency of sensor changes, offering patients a more convenient way to manage glucose levels with fewer daily interruptions. By integrating with existing insurance plans, the device aims to improve accessibility for those managing type 1 and type 2 diabetes.

The G7 system features an overall mean absolute relative difference (MARD) of 8.0% and provides glucose readings for 15.5 days. Users also benefit from a 12-hour grace period for sensor replacement.

The players

Dexcom

Founded in 1999, this medical device company specializes in the design and development of continuous glucose monitoring systems for diabetes management.

Dexcom Canada

Based in Burnaby, British Columbia, this regional office manages the distribution and regulatory compliance for the company's products within the Canadian market.

The details

The device connects directly to the Apple Watch and utilizes a mobile app with Dexcom Clarity integration to help patients track glucose patterns. Dexcom plans to expand the system’s utility by adding automated insulin delivery functionality once integration is finalized.

The Dexcom G7 15 Day system launches in Canada in November 2026.

Health Landscape

This release marks a shift toward longer-wear medical hardware that utilizes the Dexcom Clarity integration platform to streamline patient data management. It signals a move away from frequent device manual intervention, placing Dexcom in direct competition with other long-term monitoring solutions.

Adults with type 1 or type 2 diabetes will be able to access the device through public and private insurance plans starting this November. The inclusion of a 12-hour sensor replacement grace period provides extra flexibility for daily health routines and travel.

The takeaway

Patients can look forward to fewer sensor changes and improved tracking capabilities with the G7 system. Integrating the device with mobile apps remains a best practice for those wanting to monitor glucose patterns efficiently.